Next Sequence is a New York-based venture capital firm founded in 2021 that invests in pre-seed and seed-stage startups merging. See contact routes.
Next Sequence is a New York-based venture capital firm founded in 2021 that invests in pre-seed and seed-stage startups merging artificial intelligence with synthetic biology (TechBio). The firm targets check sizes of $50,000 to $100,000 and operates a distinctive 6–12 month AI accelerator program, "Next.AI," designed to transform biotech startups into SaaS-like companies by leveraging computing to accelerate R&D. Notable portfolio companies include Biomemory, Cradle, and ArgenTAG, reflecting their thesis of using AI and quantum computing to address challenges like pandemics, aging, and climate change.
Details on this firm come from filing and round data held in the StartupFundraising directory, refreshed on ingest. Founders use profiles like this one to qualify fit and to shortlist investors in New York.
Investors like Next Sequence · Full investor directory · Investor access · Company funding database